A vs. ICLR: Agilent vs. ICON Stock Comparison
How do Agilent (A) and ICON (ICLR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
Agilent (A) and ICON (ICLR) are both classified in the Life Sciences Tools & Services sub-industry within the broader Life Sciences Tools & Services industry, placing them in the closest GICS peer bucket.
| Profile Item | A | ICLR |
|---|---|---|
| Name | AgileThought, Inc. Class A Common Stock | ICON plc |
| Country/Region | United States | Ireland |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| GICS Sub-Industry | Life Sciences Tools & Services | Life Sciences Tools & Services |
| Market Capitalization | 49.28 billion USD | 15.34 billion USD |
| Currency | USD | USD |
| Exchange | NYSE | Nasdaq |
| Listing Date | November 18, 1999 | May 15, 1998 |
| Security Type | Common Stock | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | A | ICLR |
|---|---|---|
| Total Return (1Y) | 22.92% | 30.55% |
| Total Return (3Y, Annualized) | 19.33% | -6.05% |
| Total Return (5Y, Annualized) | 3.03% | -5.40% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | A | ICLR |
|---|---|---|
| Volatility (1Y, Annualized) | 33.10% | 68.62% |
| Beta (5Y) | 1.22 | 1.17 |
| Max Drawdown (5Y) | -38.09% | -76.87% |
| Avg. Volume (3M) | 2.25M | 943.50K |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | A | ICLR |
|---|---|---|
| Sharpe Ratio (1Y) | 0.56 | 0.38 |
| Sortino Ratio (1Y) | 0.96 | 0.52 |
Profitability
ROE (TTM)
Agilent (A) at 20.97% sits in the top ROE quartile, while ICON (ICLR) at 4.70% is closer to the peer norm — stronger capital efficiency for A.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
20.97%
- Max
- 109.18%
- A
- 20.97%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
4.70%
- Max
- 109.18%
- Q3
- 6.23%
- ICLR
- 4.70%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
Agilent (A) at 19.53% keeps the most of each sales dollar — above its industry’s net margin range — and ICON (ICLR) at 5.26% also retains a top-quartile share.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.53%
- A
- 19.53%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.26%
- Max
- 18.05%
- ICLR
- 5.26%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
Agilent (A) at 25.56% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
25.56%
- Max
- 83.12%
- A
- 25.56%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
10.73%
- Max
- 83.12%
- Q3
- 14.77%
- ICLR
- 10.73%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | A | ICLR |
|---|---|---|
| ROE (TTM) | 20.97% | 4.70% |
| ROA (TTM) | 8.63% | 0.85% |
| Net Margin (TTM) | 19.53% | 5.26% |
| Operating Margin (TTM) | 25.56% | 10.73% |
| Gross Margin (TTM) | 53.65% | 23.44% |
Growth
Revenue Growth
Both Agilent (A) at 6.73% and ICON (ICLR) at 0.76% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.
EPS Growth
Agilent (A) at 3.16% is around its peer norm for EPS growth, while ICON (ICLR) at -71.56% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | A | ICLR |
|---|---|---|
| Revenue Growth (YoY) | 6.73% | 0.76% |
| Revenue Growth (3Y CAGR) | 0.48% | 2.15% |
| EPS Growth (YoY) | 3.16% | -71.56% |
| EPS Growth (3Y CAGR) | 3.02% | -23.82% |
Financial Strength
Current Ratio (MRQ)
Both Agilent (A) at 2.05 and ICON (ICLR) at 1.32 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
2.05
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- A
- 2.05
- Min
- 0.10
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.32
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- ICLR
- 1.32
- Min
- 0.10
Debt / Equity (MRQ)
Both Agilent (A) at 0.56 and ICON (ICLR) at 0.38 fund their balance sheets with roughly industry-typical debt-to-equity mixes.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.56
- Max
- 1.42
- Q3
- 0.65
- A
- 0.56
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.38
- Max
- 1.42
- Q3
- 0.65
- ICLR
- 0.38
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | A | ICLR |
|---|---|---|
| Current Ratio (MRQ) | 2.05 | 1.32 |
| Debt / Equity (MRQ) | 0.56 | 0.38 |
| Net Debt / EBITDA | 1.15 | 5.55 |
Dividends
Dividend Yield (TTM)
ICON (ICLR) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a yield of 0.59%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.59%
- A
- 0.59%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
ICON (ICLR) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Agilent (A) reports a payout of 19.98%, ranking against industry peers normally.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
19.98%
- A
- 19.98%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ICLR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | A | ICLR |
|---|---|---|
| Dividend Yield (TTM) | 0.59% | 0.00% |
| Dividend Payout Ratio (TTM) | 19.98% | 0.00% |
Valuation
P/E Ratio (TTM)
Agilent (A) at 34.47 is near its industry’s usual P/E ratio, while ICON (ICLR) at 81.90 sits in the richer quartile — ICLR needs stronger growth or earnings quality to justify the premium.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
34.47
- Max
- 85.34
- Q3
- 43.46
- A
- 34.47
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
81.90
- Max
- 85.34
- ICLR
- 81.90
- Q3
- 43.46
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Agilent (A) at 6.68 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.68
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- A
- 6.68
- Q1
- 3.01
- Min
- 0.01
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.86
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- ICLR
- 1.86
- Min
- 0.01
P/B Ratio (MRQ)
ICON (ICLR) at 1.68 looks cheap against book in the lower P/B ratio quartile, while Agilent (A) at 6.69 carries a premium in the upper quartile — a clear price-to-book gap.
A
Pharmaceuticals, Biotechnology & Life Sciences industry group
6.69
- Max
- 13.53
- A
- 6.69
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
ICLR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.68
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- ICLR
- 1.68
- Min
- -5.59
Valuation Metrics
| Metric | A | ICLR |
|---|---|---|
| P/E Ratio (TTM) | 34.47 | 81.90 |
| P/S Ratio (TTM) | 6.68 | 1.86 |
| P/B Ratio (MRQ) | 6.69 | 1.68 |
| Free Cash Flow Yield (TTM) | 2.15% | 3.51% |